Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/sffYhMrCDmoedVCHhU

October 1, 2009 Donate to MMRF     Top Story  Visit the new MMRF Web site! Thanks to the many constituents who provided feedback, our new site makes it really easy to learn everything about multiple myeloma and its treatments. All information is organized by disease stage to ensure you get the information you need. You will also see that we've made it easier than ever to get involved with the MMRF and our many events. Visit the site now.   Myeloma in the News  FDA gives priority review to Velcade application The FDA has granted priority review status to Millennium: The Takeda Oncology Company for its supplemental new drug application for Velcade, which includes long-term overall survival data from the VISTA trial examining the use of Velcade-based therapy in patients with previously untreated multiple myeloma. Business Wire/News release (9/18) FDA grants orphan-drug status for Keryx myeloma drug The FDA has granted orphan-drug status to Keryx Biopharmaceuticals' multiple myeloma drug KRX-0401, or Perifosine. A late-stage trial of the drug is expected to begin by the end of the year, the company said. Forbes/The Associated Press (9/16) Amgen has positive results from Phase III trial of denosumab Amgen announced results from a Phase III trial of denosumab in advanced cancer patients with multiple myeloma or solid tumors that showed the drug delayed the median time to first on-study skeletal related event by 4.3 months. Read the release.   Research Updates  J Clin Oncol. 2009 Sep 21 Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies Cavo M, Pantani L, Tacchetti P, Pallotti MC, Brioli A, Petrucci A, Zamagni E, Tosi P. Clin Cancer Res. 2009 Sep 8 Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance Rajkumar SV. Mol Cancer Ther. 2009 Sep 1 Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE. Br J Haematol. 2009 Sep 1 Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC. Am J Hematol. 2009 Jul 30 Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ. Acta Haematol. 2009 Aug 29 Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma Buda G, Orciuolo E, Galimberti S, Cecconi N, Petrini M. Cancer Treat Rev. 2009 Sep 2 Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma Katodritou E, Dimopoulos MA, Zervas K, Terpos E. Biol Blood Marrow Transplant. 2009 Sep 2 "Short Course" Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D. Biol Blood Marrow Transplant. 2009 Sep 10 A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment Macfarland R, Hard ML, Scarborough R, Badel K, Calandra G.   News from MMRF  Hoda Kotb, Boomer Esiason and Scott Hamilton to join MMRF at 13th Annual Fall Gala, Oct. 24 The MMRF will honor Hoda Kotb, co-anchor of "Today" and "NBC Dateline" correspondent, with the Spirit of Hope Award at the 13th Annual MMRF Fall Gala. Boomer Esiason, former NFL quarterback and "NFL Today" analyst, will deliver the evening's keynote address, and Scott Hamilton, American figure skater and Olympic gold medalist, will serve as Master of Ceremonies. The Fall Gala, on Sat., Oct. 24, at the Hyatt Regency in Greenwich, Conn., will advance the MMRFs innovative research portfolio. Click here, call 888-584-5463 or e-mail mmrf@benefitoffice.org to purchase tickets, donate an auction item or join a committee. Ready, set, go! 2009 Race for Research 5k walk/runs are scheduled nationally Help raise much-needed awareness and funds for myeloma research by participating in the annual MMRF Race for Research 5k walk/runs in Philadelphia (Sat., Oct. 3), Atlanta (Sun., Nov. 1) and Washington, D.C., (Sun., Nov. 15)! These fun, family-friendly events are a great way to show your support. Find information, register as an individual, form a team or sponsor the event here. Run a marathon or half marathon in 2010 for the MMRF Team! The MMRF Marathon/Half Marathon Program has just released its slate of marathons and half marathons for 2010. We've added many races in a variety of locations, including the Boston Marathon. Help the MMRF reach the ultimate finish line, a cure for multiple myeloma, by joining the MMRF Marathon and Half Marathon Program. All funds raised through this exciting program will support research that will result in new treatments and, one day, a cure. To learn more, e-mail hoffmannj@themmrf.org. Learn more about MMRF -> About Myeloma  |  About MMRF  |  Donate  |  Get Involved  |  Medical Programs   SmartQuote  At the present rate of progress, it is almost impossible to imagine any technical feat that cannot be achieved -- if it can be achieved at all -- within the next few hundred years." --Arthur C. Clarke, British author and inventor   Subscriber Tools     Search past news |  Privacy policy   Editorial Team Lead Editor:  Kathryn Doherty             Recent MMRF SmartBrief Issues: Thursday, September 17, 2009 Thursday, September 03, 2009 Thursday, August 20, 2009 Thursday, August 06, 2009 Thursday, July 23, 2009     Mailing Address: SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005     © 1999-2011 SmartBrief, Inc.® Legal Information